期刊文献+

抗凝药物对血小板形态影响的电镜观察 被引量:3

Electron Microscopic Observation on Morphology of Platelets Effected by Anticoagulating Agents
下载PDF
导出
摘要 利用H-300透射电镜观察43例冠心病患者血小板形态及24例用抗凝药物治疗后的血小板形态改变,同时观察血液流变学及甲皱微循环变化。结果表明:冠心病患者聚集型血小板明显增多,树突型血小板突起多而长。血粘度增高,甲皱微循环异常。用潘生丁、阿斯匹林、低分子右旋醣酐等药物治疗后,聚集型血小板减少,聚集堆以不同方式离散或出现解聚倾向,树突型血小板突起变少变短。血粘度降至正常范围。甲皱徵循环改善。几种药物中以阿斯匹林效果最佳。 Morphology of platelets in 43 cases of the patients with coronary heart disease (CHD)and 24 cases of the patients treated with anticoagulating agents was observed by transmiting electron microscope, meanwhile the hemorheology and the hyponychial mi-crocirculation of the patients were monitored. The results showed that: Of the CHD patients, the platelets of aggregating type were increased significantly,the processes of dendritic type platelets were more and long,the hemoviscosity was high,hyponychial micro-circulation was abnormal. After the patients were treated with persantin,aspirin and dextran 40,the platelets of aggregating type were decreased and the platelets aggregating piles dispersed by different ways or presented a disaggregating trend,the processes of dendritic type platelets were less and short. The hemoviscosity lowered to normal range,the hyponychial microcirculation became better than that of pretreated with anticoagulation agents. Of the studied agents,aspirin showed the best effect.
出处 《中国医学影像学杂志》 CSCD 1995年第1期48-50,共3页 Chinese Journal of Medical Imaging
关键词 抗凝药物 血小板形态 超微结构 电镜观察 冠心病 血液流变学 甲皱微循环 anticoagulating agents morphology platelet ultrastructure
  • 相关文献

参考文献1

  • 1程时.血小板与动脉粥样硬化和冠心病的关系[J]生理科学进展,1978(01).

同被引文献20

  • 1肖纫秋,吴家祥,张凤兰.实验性糖尿病大鼠血小板扫描电镜观察[J].白求恩医科大学学报,1990,16(3):219-221. 被引量:1
  • 2胡群,王令仪.地塞米松冲击疗法治疗小儿特发性血小板减少性紫癜(附治疗前后血小板电镜观察)[J].武汉医学杂志,1996,20(2):74-75. 被引量:3
  • 3曲淑贤,吕广艳,田晓光,高船舟,崔颖.介绍一种血小板整体黏附电镜样品制备方法[J].大连医科大学学报,2006,28(6):500-500. 被引量:1
  • 4Kajitani M,Aguinaga M,Johnson CE,et al. Use of plasma exchange and heparin during cardiopulmonary bypass for a patient with heparin induced thrombocytopenia: a case report. J Card Surg,2001, 16(4): 313
  • 5Saltissi D, Morgan C, Westhuyzen J, et al. Comparison of lowmolecular-weight heparin(enoxaparin sodium)and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant, 1999, 14(11): 2698
  • 6Kramer L, Gendo A, Madl C,et al. Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. Am J Kidney Dis, 2000,36(6): 1193
  • 7Hafner G,Klingle R,Wandel B,et al. Laboratory control of minimal heparinization during hemodialysis in patients with a risk of hemorrhage. Blood Coagul Fibrilysis, 1994, 5: 211
  • 8Schrader J, Stibbe W, Armstrong VW, et al. Comparison of low molecular weight heparin to standard in hemodialysis/hemofil-tration. Kidney Int, 1988, 33:890
  • 9Lai KN,Wang AY, Ho K, et al. Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis, 1996,28(5):721
  • 10Mally T, Langhrone P, Elton RA, et al. Platelet size in stroke patients. Stroke, 1995, 26:995

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部